IO120

News alerts, weekly reports and conference planners

Company:

IO Biotech

Drug class:

PD-L2 inhibitor

‹

›

4years

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. (clinicaltrials.gov)

P2, N=19, Completed, Lars Møller Pedersen | Active, not recruiting --> Completed

4 years ago

Trial completion • IO biomarker

IGH (Immunoglobulin Heavy Locus)

IO103 • IO120

5years

Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia. (clinicaltrials.gov)

P2, N=20, Active, not recruiting, Lars Møller Pedersen | Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Mar 2021

5 years ago

Clinical • Trial completion date • Trial primary completion date • IO biomarker

IGH (Immunoglobulin Heavy Locus)

IO103 • IO120

over5years

Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia. (clinicaltrials.gov)

P2, N=20, Active, not recruiting, Lars Møller Pedersen | Recruiting --> Active, not recruiting

over 5 years ago

Clinical • Enrollment closed • PD(L)-1 Biomarker • IO biomarker

IGH (Immunoglobulin Heavy Locus)

IO103 • IO120